RecruitingPhase 3NCT06079879
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Bomedemstat(drug)
- Enrollment
- 340 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496), Glendale, Arizona, United States
- Los Angeles Cancer Network ( Site 3491), Glendale, California, United States
- Stanford Cancer Institute ( Site 0107), Stanford, California, United States
- The Lundquist Institute ( Site 3423), Torrance, California, United States
- University of Colorado Anschutz Medical Campus ( Site 3425), Aurora, Colorado, United States
- Tufts Medical Center ( Site 3408), Boston, Massachusetts, United States
- University of Michigan ( Site 0008), Ann Arbor, Michigan, United States
- Henry Ford Hospital ( Site 3413), Detroit, Michigan, United States
- Optum Care Cancer Center ( Site 3497), Las Vegas, Nevada, United States
- Roswell Park Cancer Institute ( Site 3421), Buffalo, New York, United States
- Duke University Health System (DUHS) ( Site 0016), Durham, North Carolina, United States
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400), Winston-Salem, North Carolina, United States
- Medical University of South Carolina-Hollings Cancer Center ( Site 3426), Charleston, South Carolina, United States
- University of Virginia ( Site 3422), Charlottesville, Virginia, United States
- VCU Health Adult Outpatient Pavillion ( Site 3416), Richmond, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06079879 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.